Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Risperidone plasma concentrations are associated with hyperprolactinemia in autism spectrum disorder children: The impact of CYP2D6 polymorphisms
Authors: Monpat Chamnanphon
Natchaya Vanwong
Santirhat Prommas
Napatrupron Koomdee
Rattanaporn Sukprasong
Jiratha Rachanakul
Nutthan Nuntharadthanaphong
Yaowaluck Hongkaew
Shobana John
Nattawat Ngamsamut
Nopphadol Nuntamool
Penkhae Limsila
Chonlaphat Sukasem
Ramathibodi Hospital
Chulalongkorn University
Bumrungrad International Hospital
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Thailand Ministry of Public Health
Payap University
Faculty of Medicine, Srinakharinwirot University
Keywords: Medicine;Psychology
Issue Date: 1-Aug-2022
Citation: Research in Autism Spectrum Disorders. Vol.96, (2022)
Abstract: Background: Risperidone causes hyperprolactinemia by blocking D2 receptors on lactotrophs anterior pituitary, which prevents prolactin secretion inhibition. Risperidone is converted to 9-hydroxyrisperidone by the CYP2D6 enzyme. Polymorphisms in CYP2D6 may affect serum prolactin and could be a predictor of hyperprolactinemia. The goal of this study was to see if there was an association between CYP2D6 variants, risperidone dose, clinical data and serum prolactin levels in Thai children and adolescents with autism spectrum disorder (ASD). Method: In 107 Thai ASD patients on risperidone, allele-specific primer extension and multiplex PCR platforms were used to genotype the CYP2D6 gene. The chemiluminescence immunoassay (CLIA) technique was used to measure fasting serum prolactin levels. Results: The median serum prolactin level was 16.25 ng/mL (IQR; 10.43-22.18), and patients with CYP2D6*1/*5 (6.54%) had substantially lower prolactin levels than those with CYP2D6*1/*1 [median; 11.2 ng/mL (IQR; 3.95-21.10) vs. 21.3 (IQR; 14.43-32.18), p=0.032]. CYP2D6*1/*10, *10/*10, and *10/*41 produced less prolactin than *1/*1 (wild type). Furthermore, gender and risperidone dose were associated with significantly different prolactin levels with p-value 0.02 and 0.006, respectively. Multivariate analysis showed a significant association of serum prolactin level with body mass index and risperidone dose (p<0.05). Conclusions: Our study showed that CYP2D6 carriers of absent and decreased functional alleles had lower serum prolactin levels in Thai ASD patients treated with risperidone treatment; this is important to clinicians, indicating that they should consider about CYP2D6 genotyping before beginning risperidone in ASD patients. CYP2D6 genotypes might be a predictor for levels of prolactin in clinical treatment.
ISSN: 18780237
Appears in Collections:Scopus 2022

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.